Integral Molecular, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Integral Molecular, Inc.
Plus deals involving Helixmith/Wacker, Sosei Heptares/Metrion, Ono/Ribon, Asahi Kasei/Lilly, Citrine/Diurnal, Mitsubishi Tanabe/Aquestive, Immunotech/T-Cure, TRIGR/Elpiscience, Daiichi Sankyo/ViGeneron
Daiichi Sankyo pays $150m upfront to commercialize Esperion's cholesterol drug and combination in Europe, while Gilead enters major deal worth up to $785m with Korea's Yuhan to bolster its NASH portfolio. Samsung taps 3SBio to build its biosimilars business in China.
The latest biopharma industry appointments include a new chief patient officer at Servier, executives at Merck KGaA, Unum and Aduro, as well as several board updates.
As an exclusive partner of U.S. Partners HealthCare International (PHI), Saint Lucia Consulting has received investment funds from Sequoia Capital and will provide cancer evaluation services (CES) for Chinese patients who are seeking medical treatment in U.S.
- Large Molecule